The findings reviewed by GME stated that the Global Non-invasive Prenatal
Testing Market will expand with a CAGR
value of 11.5 percent from 2021 to 2026. The rise in the prevalence of genetic
diseases, rapid acceptance of next-generation testing, innovative product
releases, and an increase in the number of non-invasive prenatal testing
service providers are driving the non-invasive prenatal testing market.
Browse 159 Market Data
Tables and 119 Figures spread through 189 Pages and in-depth TOC on "Global
Non-invasive Prenatal Testing Market -
Forecast to 2026"
https://www.globalmarketestimates.com/market-report/global-non-invasive-prenatal-testing-market-3045
By
Gestation Period (0-12 Weeks, 13-24 Weeks, and 25-36 Weeks), By Risk Type (High
& Average Risk and Low Risk), By Method (Ultrasound Detection, Biochemical
Screening Tests, and Cell-Free DNA in Maternal Plasma Tests), By Technology
(NGS, Array Technology, PCR, and Other Technologies), By Product (Consumables & Reagents and
Instruments), By End-User (Hospitals & Clinics and Diagnostic
Laboratories), By Region
(North America, Asia Pacific, CSA, Europe, and the Middle East and Africa);
End-User Landscape, Company Market Share Analysis & Competitor Analysis
Key
Market Insights
· The advancements in testing technology and the
growth of bioinformatics are expected to increase the demand for non-invasive
prenatal testing.
·
The largest share of the 13-24 weeks segment is mainly attributed to the
fact that the majority of NIPT is performed during the second trimester, in
conjunction with other tests.
·
The rising number of
high-risk pregnancies among women over the age of 35 has resulted in the
domination of the high and medium risk segments.
·
The largest share of cell-free DNA-based NIPT segment is mainly
attributed to the ongoing technological advancements.
·
The NGS segment held the dominant share of the market among non-invasive
prenatal testing technologies in 2020.
· The diagnostic laboratories
segment has the largest share owing to the high availability of advanced
diagnostic instruments.
·
Natera, Inc., Illumina
Inc., MedGenome Labs Ltd., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche Ltd.,
Centogene N.V., Genesis Genetics, Myriad Women’s Health Inc., Laboratory Corp.
of America Holdings, Progenity Inc., Qiagen, Quest Diagnostics Inc., among
others, are the major vendors competing in the Non-invasive Prenatal Testing
market.
Browse the Report @ https://www.globalmarketestimates.com/market-report/global-non-invasive-prenatal-testing-market-3045
Gestation Period Outlook (Revenue, USD
Billion, 2021-2026)
·
0-12 Weeks
·
13-24 Weeks
·
25-36 Weeks
Risk Type Outlook
(Revenue, USD Billion, 2021-2026)
·
High & Average Risk
·
Low Risk
Method Outlook
(Revenue, USD Billion, 2021-2026)
·
Ultrasound Detection
·
Biochemical Screening Tests
·
Cell-Free DNA in Maternal Plasma Tests
Technology Outlook
(Revenue, USD Billion, 2021-2026)
·
NGS
·
Array Technology
·
PCR
·
Other Technologies
Product Outlook
(Revenue, USD Billion, 2021-2026)
·
Consumables & Reagents
·
Instruments
End-User Outlook
(Revenue, USD Billion, 2021-2026)
·
Hospitals & Clinics
·
Diagnostic Laboratories
Regional Outlook
(Revenue, USD Billion, 2021-2026)
North America
- The
U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of
Europe
Asia Pacific
- China
- India
- Japan
- South
Korea
- Australia
- Rest of
APAC
Central
& South America
- Brazil
- Argentina
- Rest of
CSA
Middle
East & Africa
- Saudi
Arabia
- UAE
- Rest of
MEA
Contact:
Tracy Simon
Email address: tracy.simon@globalmarketestimates.com
Phone
Number: +16026667238
Website:
https://www.globalmarketestimates.com/
Check
our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php
